A Phase I, Sponsor-Open, Investigator-Blinded, Subject-Blinded, Multi-Center, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Administration of RO7020531: (1). Single and Multiple Ascending Doses in Healthy Male and Female Subjects; (2). 6-Week Treatment of Virologically Suppressed Patients With Chronic Hepatitis B Virus Infection

Trial Profile

A Phase I, Sponsor-Open, Investigator-Blinded, Subject-Blinded, Multi-Center, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Administration of RO7020531: (1). Single and Multiple Ascending Doses in Healthy Male and Female Subjects; (2). 6-Week Treatment of Virologically Suppressed Patients With Chronic Hepatitis B Virus Infection

Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Nov 2017

At a glance

  • Drugs RO 7020531 (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 20 Nov 2017 Planned number of patients changed from 110 to 140.
    • 05 Oct 2017 Planned End Date changed from 19 Apr 2019 to 24 Apr 2019.
    • 05 Oct 2017 Planned primary completion date changed from 19 Apr 2019 to 24 Apr 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top